Dystrophic Anagen Effluvium Occurring During Pegylated Interferon-α-2a/Ribavirin Therapy

    March 2015 in “ Hepatitis Monthly ”
    Kamuran Türker, Betül Taş, Murat Özkaya … Seza Tetikkurt
    Studysummary This case report identified dystrophic anagen effluvium as a previously unreported dermatological side effect of PEG-INF-α-2a/RBV combination therapy in a patient with chronic hepatitis C infection.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on brieflands.com →
    Discuss this study in the Community →

    Research cited in this study 7

    1. Hair and Scalp Evaluation: The Trichogram Actas Dermo-Sifiliográficas · 2013
    2. Irreversible Alopecia Universalis During Treatment With Pegylated Interferon-Ribavirin for Chronic Hepatitis C Virus Infection: Case Report and Literature Review Hepatology Research · 2012
    3. Chemotherapy-Induced Hair Loss PubMed · 2010
    4. A Review of Adverse Cutaneous Drug Reactions Resulting from the Use of Interferon and Ribavirin Canadian Journal of Gastroenterology · 2009
    5. Reversible Alopecia Universalis Secondary to PEG-Interferon Alpha-2b and Ribavirin Combination Therapy in a Patient with Chronic Hepatitis C Virus Infection European Journal of Gastroenterology & Hepatology · 2007
    6. Hair Loss Pattern Due to Chemotherapy-Induced Anagen Effluvium: A Cross-Sectional Observation Dermatology · 2007
    7. Alopecia Areata During Interferon Alpha-2b and Ribavirin Therapy Dermatology · 2002